To test our hypothesis, we measured the plasma AACS signatures from N = 33 hormone receptor positive, HER2 negative advanced breast cancer patients who were recommended for but had not yet started CDKi treatment, meaning that they were baseline naïve for CDKi’s. Here, ERBB2 is linked to breast carcinoma.